arrow
M

Mothaffar F. Rimawi

baylor college of medicine
H指数:52
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative

系统评价数据与试验适配性以用于肿瘤学试验模拟:CARE倡议的经验发现

2026-06-040
OA
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results

Tucatinib-曲妥珠单抗-卡培他滨治疗HER2乳腺癌女性软脑膜转移: TBCRC049 2期研究结果

2026-03-180
OAAI
Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative

临床意义、以患者为中心的终点指标在乳腺癌真实世界证据生成中的应用:多学科TRIUMPH倡议的视角

2026-03-170
OAAI
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)

早期三阴性乳腺癌中视觉和计算评估的肿瘤浸润淋巴细胞预后价值(TBCRC-030)

2025-11-010
PRE
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

检测细胞游离DNA中酪氨酸激酶抑制剂异质性耐药机制

2025-09-090
OAAI
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
BREAST
IF7.9
2025-06-010
OAAI
AVIATOR/ TBCRC045: A randomized phase II study of vinorelbine (N) plus trastuzumab (H) alone or combined with avelumab (A) plus /- utomilumab (U) in patients (pts) with HER2+metastatic breast cancer (MBC) (NCT03414658)
2024-05-020
PRE
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
2024-05-020
PRE
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

TBCRC 030中三阴性乳腺癌新辅助化疗后循环肿瘤DNA与残余肿瘤负荷的关系

2023-10-0113
OAAI
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
2023-08-313
OA
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer
2023-08-014
OA